Key player in Pershing Square's Valeant bet leaving firm
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Valeant (VRX) Derm NRx Up 1% Week-Over-Week, ophth NRx Down 5.1% - RBC
May 13, 2016 12:48 PM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 1.0% WoW, ophth NRx were down 5.1% WoW, and Addyi NRx were down 3.6% WoW.
Miehm commented, "For the week ending May 6th, new derm scripts (NRx) were up 1.0% vs. up 2.2% the prior... More
